Efficacy of Gemfibrozil As an Adjunct to Sertraline in Major Depressive Disorder, a Double-Blind, Randomized, and Placebo-Controlled Clinical Trial

Efficacy of Gemfibrozil As an Adjunct to Sertraline in Major Depressive Disorder, a Double-Blind, Randomized, and Placebo-Controlled Clinical Trial Publisher

Zandifar A¹ ; Badrfam R² ; Shamabadi A² ; Jalilevand S² ; Pourmirbabaei S² ; Torkamand F² ; Sahebolzamani E² ; Akhondzadeh S²

Show Affiliations

1. Imam Ali Hospital, Alborz University of Medical Sciences, Karaj, Iran
2. Psychiatric Research Center, Roozbeh Psychiatric Hospital, Tehran University of Medical Sciences, Tehran, Iran

Source: Iranian Journal of Psychiatry Published:2021

Abstract

Objective: Major depressive disorder (MDD) is predicted to be the first cause of burden of disease. The antidepressant activity of gemfibrozil has been recently considered. This study was designed to evaluate the effectiveness of gemfibrozil as a sertraline adjunct in treating patients with MDD. Method: A total of 46 patients with MDD based on the DSM-V criteria with a minimum score of 22 on the 17-item Hamilton Rating Scale for Depression (HAM-D) were randomized to receive either 300 mg daily gemfibrozil or placebo in addition to 100 mg sertraline for 8 weeks in a randomized, double-blind placebo-controlled trial. Patients were evaluated for response to treatment using the HAM-D score at baseline and weeks 2, 4, and 8. Results: Forty-five patients completed the study and took part in all follow-up visits. Repeated measure ANOVA with a Greenhouse-Geisser correction showed a significant difference for time×treatment interaction on within-subjects HAM-D scores [p-value= 0.026]. A significant difference was seen in time [p-value < 0.001]. The test of between-subject effects also showed a significant effect of treatment on HAM-D scores at weeks 2, 4, and 8 [p-value = 0.07]. Using Kaplan-Meier estimate curves, time to remission periods were significantly different between the 2 trial arms [Log-Rank p-value = 0.003]. Conclusion: Gemfibrozil is an effective adjunctive treatment in MDD and can be used to reduce depression symptoms. Copyright © 2021 Tehran University of Medical Sciences.

2. Cinnamomum Tamala As an Adjuvant Therapy in the Treatment of Major Depressive Disorder: A Double-Blind, Randomized, Placebo-Controlled Clinical Trial With Placebo Control, Advances in Integrative Medicine (2020)

3. Palmitoylethanolamide As Adjunctive Therapy in Major Depressive Disorder: A Double-Blind, Randomized and Placebo-Controlled Trial, Journal of Affective Disorders (2018)

4. L-Carnosine As Adjunctive Therapy in Children and Adolescents With Attention-Deficit/Hyperactivity Disorder: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial, Journal of Child and Adolescent Psychopharmacology (2018)

5. Efficacy and Safety of Pentoxifylline Combination Therapy in Major Depressive Disorder: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial, International Clinical Psychopharmacology (2021)

6. Comparison of Vortioxetine and Sertraline for Treatment of Major Depressive Disorder in Elderly Patients: A Double-Blind Randomized Trial, Journal of Clinical Pharmacy and Therapeutics (2020)

7. Synergistic Antidepressant Effects of Citalopram and Sb-334867 in the Rem Sleep-Deprived Mice: Possible Role of Bdnf, Pharmacology Biochemistry and Behavior (2022)

8. L-Carnosine As an Add-On to Risperidone for Treatment of Negative Symptoms in Patients With Stable Schizophrenia: A Double-Blind, Randomized Placebo-Controlled Trial, Psychiatry Research (2018)

Experts (# of related papers)

View all Related Experts

Shahin Akhondzadeh Basti (7)

Ahmad Ali Noorbala Tafti (1)

Style	Citing Format
MLA	Zandifar A, et al.. "Efficacy of Gemfibrozil As an Adjunct to Sertraline in Major Depressive Disorder, a Double-Blind, Randomized, and Placebo-Controlled Clinical Trial." Iranian Journal of Psychiatry, vol. 16, no. 1, 2021, pp. 52-59.
APA	Zandifar A, Badrfam R, Shamabadi A, Jalilevand S, Pourmirbabaei S, Torkamand F, Sahebolzamani E, Akhondzadeh S (2021). Efficacy of Gemfibrozil As an Adjunct to Sertraline in Major Depressive Disorder, a Double-Blind, Randomized, and Placebo-Controlled Clinical Trial. Iranian Journal of Psychiatry, 16(1), 52-59.
Chicago	Zandifar A, Badrfam R, Shamabadi A, Jalilevand S, Pourmirbabaei S, Torkamand F, Sahebolzamani E, Akhondzadeh S. "Efficacy of Gemfibrozil As an Adjunct to Sertraline in Major Depressive Disorder, a Double-Blind, Randomized, and Placebo-Controlled Clinical Trial." Iranian Journal of Psychiatry 16, no. 1 (2021): 52-59.
Harvard	Zandifar A et al. (2021) 'Efficacy of Gemfibrozil As an Adjunct to Sertraline in Major Depressive Disorder, a Double-Blind, Randomized, and Placebo-Controlled Clinical Trial', Iranian Journal of Psychiatry, 16(1), pp. 52-59.
Vancouver	Zandifar A, Badrfam R, Shamabadi A, Jalilevand S, Pourmirbabaei S, Torkamand F, et al.. Efficacy of Gemfibrozil As an Adjunct to Sertraline in Major Depressive Disorder, a Double-Blind, Randomized, and Placebo-Controlled Clinical Trial. Iranian Journal of Psychiatry. 2021;16(1):52-59.
BibTex	@article{ author = {Zandifar A and Badrfam R and Shamabadi A and Jalilevand S and Pourmirbabaei S and Torkamand F and Sahebolzamani E and Akhondzadeh S}, title = {Efficacy of Gemfibrozil As an Adjunct to Sertraline in Major Depressive Disorder, a Double-Blind, Randomized, and Placebo-Controlled Clinical Trial}, journal = {Iranian Journal of Psychiatry}, volume = {16}, number = {1}, pages = {52-59}, year = {2021} }
RIS	TY - JOUR AU - Zandifar A AU - Badrfam R AU - Shamabadi A AU - Jalilevand S AU - Pourmirbabaei S AU - Torkamand F AU - Sahebolzamani E AU - Akhondzadeh S TI - Efficacy of Gemfibrozil As an Adjunct to Sertraline in Major Depressive Disorder, a Double-Blind, Randomized, and Placebo-Controlled Clinical Trial JO - Iranian Journal of Psychiatry VL - 16 IS - 1 SP - 52 EP - 59 PY - 2021 ER -

Science Communicator Platform

Authors

Authors Affiliations

Abstract